bluuebunny/crossref_metadata_2025_split huggingface dataset:
Epidemiological study of the subtype frequency of systemic amyloidosis listed in the Annual of the Pathological Autopsy Cases in Japan
Authors: Yamaguchi Aina , Tasaki Masayoshi , Ueda Mitsuharu , Ando Yukio , Naiki Hironobu 
Published: December 2023

AbstractClinical presentation of systemic amyloidosis differs among subtypes, and accurate subtype classification is important for choosing the treatment. Amyloid transthyretin (ATTR) amyloidosis was the predominant among the recently consulted amyloidosis cases in Japan. To reveal the latest subtype frequency of systemic amyloidosis among autopsy cases in Japan. We analyzed systemic amyloidosis cases autopsied from January 2017 to December 2018, that were listed in the Annuals of the Pathological Autopsy Cases in Japan, Volumes 60 and 61. When the subtype was unclear, we performed a questionnaire survey, immunohistochemistry with in‐house rabbit polyclonal anti‐κ116–133, anti‐λ118–134, and anti‐transthyretin115–124 antibodies, and proteomic analysis. Out of 481 systemic amyloidosis cases listed in the Annuals, 411 cases were available for analysis (85.4%). We classified 399 of these systemic amyloidosis cases. ATTR was the most common subtype (44.4%, n = 177), followed by amyloid immunoglobulin light chain (AL) (38.8%, n = 155). Amyloid A and amyloid β2‐microglobulin were 9.3% (n = 37) and 6.0% (n = 24), respectively. Double deposition of amyloid was identified in 1.6% (n = 6). In 168 cases (42.1%), systemic amyloidosis was the main cause of death. Of these cases, AL was the most common subtype (47.6%, n = 80), followed by ATTR (41.1%, n = 69). ATTR is the most predominant subtype among the current autopsy cases in Japan.
Treatable traits models of care
Authors: McDonald Vanessa M. , Holland Anne E. 
Published: December 2023

AbstractTreatable traits is a personalized approach to the management of respiratory disease. The approach involves a multidimensional assessment to understand the traits present in individual patients. Traits are phenotypic and endotypic characteristics that can be identified, are clinically relevant and can be successfully treated by therapy to improve clinical outcomes. Identification of traits is followed by individualized and targeted treatment to those traits. First proposed for the management of asthma and chronic obstructive pulmonary disease (COPD) the approach is recommended in many other areas of respiratory and now immunology medicine. Models of care for treatable traits have been proposed in different diseases and health care setting. In asthma and COPD traits are identified in three domains including pulmonary, extrapulmonary and behavioural/lifestyle/risk‐factors. In bronchiectasis and interstitial lung disease, a fourth domain of aetiological traits has been proposed. As the core of treatable traits is personalized and individualized medicine; there are several key aspects to treatable traits models of care that should be considered in the delivery of care. These include person centredness, consideration of patients' values, needs and preferences, health literacy and engagement. We review the models of care that have been proposed and provide guidance on the engagement of patients in this approach to care.
The effects of cross‐border acquisitions on firms' productivity in the EU
Authors: Gregori Wildmer Daniel , Martinez‐Cillero Maria , Nardo Michela 
Published: December 2023

AbstractThis study empirically investigates the extent to which firms in the European Union, once acquired through a cross‐border acquisition, show different productivity levels as compared to those firms that have not been acquired. Our identification strategy relies on the combination of Propensity Scores and the Staggered Difference‐in‐Difference estimator, using firms' balance sheet data for the years 2008–2018. We find that cross‐border acquisitions decrease the productivity of the acquired firms, especially in the manufacturing sector, both high‐ and low‐tech. We also find evidence of origin and sector heterogeneity. Firms targeted by acquirers with ultimate owners originating in emerging market economies and Offshore Financial Centres also decrease productivity of target firms operating in high‐tech manufacturing sectors.
Counselor bias and contraceptive counseling for women: a scoping review protocol
Authors: McMurtery Reagan E. , Palokas Michelle 
Published: December 2023

Objective:
The objective of this review is to identify factors, tools, and interventions related to counselor biases and contraceptive counseling in women.

Introduction:
Contraceptive counseling is the transfer of knowledge regarding contraceptive methods to aid an individual in selecting, discontinuing, or changing contraception. The counselor should deliver information based on the patient’s needs and preferences. The type and quality of the contraceptive information women are provided should not vary based on social or physical factors, such as age, race, religion, sexual orientation, education level, sexual preference, or weight; however, professional bias continues to be a concern in health care. The results of this review may further the understanding of counselor bias and contraceptive counseling.

Inclusion criteria:
This scoping review will consider studies that include health care professionals providing contraceptive counseling to female patients in any setting or geographic location. Studies reporting on factors, tools, and interventions related to counselor bias and contraceptive counseling will be included.

Methods:
Databases to be searched are MEDLINE, CINAHL, Scopus, Web of Science, ScienceDirect, JBI Evidence-based Practice Database, Europe PubMed Central, and Cochrane Library. Sources of gray literature will include ProQuest Dissertations and Theses, PaperFirst, and MedNar. The review will include studies published in English from 1994 onward and follow the JBI methodology for scoping reviews. Two independent reviewers will screen the titles and abstracts, then full texts. Data from relevant studies will be extracted using a tool created by the reviewers. The results will be presented as a narrative summary and in diagrammatic or tabular format.

Review registration:
Open Science Framework https://osf.io/judp5
Physiology of γ-aminobutyric acid production by
Akkermansia muciniphila
Authors: Konstanti Prokopis , Ligthart Kate , Fryganas Christos , Constantinos Patinios , Smidt Hauke , de Vos Willem M. , Belzer Clara 
Published: December 2023

ABSTRACT

Gut bacteria hold the potential to produce a broad range of metabolites that can modulate human functions, including molecules with neuroactive potential. One such molecule is γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter of the central nervous system in animals. Metagenomic analyses suggest that the genomes of many gut bacteria encode glutamate decarboxylase (GAD), the enzyme that catalyzes GABA production. The genome of
Akkermansia muciniphila
, a mucin specialist and potential next-generation probiotic from the human gut, is predicted to encode GAD, suggesting a contributing role in GABA production in the human gut. In this study,
A. muciniphila
was grown in batch cultures with and without pH control. In both experiments,
A. muciniphila
was found to produce GABA as a response to acid (pH <5.5), although only when GABA precursors, either glutamate or glutamine, were present in the medium. Proteomic analysis comparing
A. muciniphila
grown with and without precursors at pH 4 did not show a difference in GAD expression, suggesting that it is expressed regardless of the presence of GABA precursors. To further investigate the function of
A. muciniphila
GAD, we heterologously expressed the
gad
gene (encoded by locus tag Amuc_0372) with a His tag in
Escherichia coli
and purified the GAD protein. Enzyme assays showed GAD activity in a pH range between 4 and 6, with the highest specific activity at pH 5 of 144 ± 16 µM GABA/min/mg. Overall, our results demonstrate the ability of
A. muciniphila
to produce GABA as an acid response and unravel the conditions under which GABA production in
A. muciniphila
occurs.

IMPORTANCE

Akkermansia muciniphila
is considered to be a beneficial bacterium from the human gut, but the exact mechanisms by which
A. muciniphila
influences its host are not yet fully understood. To this end, it is important to identify which metabolites are produced and consumed by
A. muciniphila
that may contribute to a healthy gut. In the present study, we demonstrate the ability of
A. muciniphila
to produce γ-aminobutyric acid (GABA) when grown in an acidic environment, which often occurs in the gut. GABA is the major inhibitory neurotransmitter in the central nervous system and is present in the human gut. For this reason, it is considered an important bacterial metabolite. Our finding that
A. muciniphila
produces GABA in acidic environments adds to the growing body of understanding of its relationship with host health and provides an explanation on how it can survive acid stress in the human gut.
Complete genome sequence of
Oenococcus oeni
strain K19-3 isolated from grape must
Authors: Mardanov Andrey V. , Beletsky Alexey V. , Vasyagin Egor A. , Tanashchuk Tatiana N. , Shalamitskiy Maxim Yu. , Ravin Nikolai V. 
Published: December 2023

ABSTRACT

The lactic acid bacteria
Oenococcus oeni
spp. are of significant interest in winemaking due to their ability to carry out malolactic fermentation, thereby improving the organoleptic properties of wine. Here we report the complete circular genome sequence of the
Oenococcus oeni
strain К19-3, isolated from red grape must at Crimean wineries.
Effects of theABCC8R1420H loss-of-function variant on beta-cell function, diabetes incidence, and retinopathy
Authors: Vazquez Arreola Elsa , Knowler William C , Baier Leslie J , Hanson Robert L 
Published: December 2023

IntroductionTheABCC8gene regulates insulin secretion and plays a critical role in glucose homeostasis. The effects of anABCC8R1420H loss-of-function variant on beta-cell function, incidence of type 2 diabetes, and age-at-onset, prevalence, and progression of diabetes complications were assessed in a longitudinal study in American Indians.Research design and methodsWe analyzed beta-cell function through the relationship between insulin secretion and insulin sensitivity in members of this population without diabetes aged ≥5 years using standard major axis regression. We used hierarchical logistic regression models to study cross-sectional associations with diabetes complications including increased albuminuria (albumin-to-creatinine ratio (ACR) ≥30 mg/g), severe albuminuria (ACR ≥300 mg/g), reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2), and retinopathy. This study included 7675 individuals (254 variant carriers) previously genotyped for the R1420H with available phenotypic data and with a median follow-up time of 13.5 years (IQR 4.5–26.8).ResultsVariant carriers had worse beta-cell function than non-carriers (p=0.0004; on average estimated secretion was 22% lower, in carriers), in children and adults, with no difference in insulin sensitivity (p=0.50). At any body mass index and age before 35 years, carriers had higher type 2 diabetes incidence. This variant did not associate with prevalence of increased albuminuria (OR 0.87, 95% CI 0.66 to 1.16), severe albuminuria (OR 0.96, 95% CI 0.55 to 1.68), or reduced eGFR (OR 0.44, 95% CI 0.18 to 1.06). By contrast, the variant significantly associated with higher retinopathy prevalence (OR 1.74, 95% CI 1.19 to 2.53) and this association was only partially mediated (<11%) by glycemia, duration of diabetes, risk factors of retinopathy, or insulin use. Retinopathy prevalence in carriers was higher regardless of diabetes presence.ConclusionsTheABCC8R1420H variant is associated with increased risks of diabetes and of retinopathy, which may be partially explained by higher glycemia levels and worse beta-cell function.
Improved vaccine coverage for First Nations children receiving first dose on-reserve: a retrospective cohort study in western Canada
Authors: MacDonald Shannon E , Graham Bonny , King Keith D , Huang Li , Svenson Lawrence W. , Nelson Gregg 
Published: December 2023

IntroductionFragmentation in immunisation reporting systems pose challenges in measuring vaccine coverage for First Nations children in Canada. Some Nations have entered into data-sharing agreements with the province of Alberta’s health ministry, enabling novel opportunities to calculate coverage.MethodsPartnering with a First Nations community in Alberta, this retrospective cohort study calculated routine childhood vaccine coverage. Administrative data for vaccines delivered within and outside the community were linked to calculate partial and complete immunisation coverage in 2013–2019 at ages 2 and 7 years for children living in the community. We also compared vaccine coverage each year for (a) children who were and were not continuous community residents and (b) children who received or not their first vaccine at the on-reserve community health centre. We also calculated the mean complete coverage across all study years with 95% CIs.ResultsFor most vaccines, coverage was higher (p<0.05) at ages 2 and 7 years for children that received their first vaccine at the First Nations health centre, compared with those who received their first dose elsewhere. For example, for pneumococcal vaccine, the mean level of complete coverage in 2-year-olds was 55.7% (52.5%–58.8%) for those who received their first vaccine in the community, compared with 33.3% (29.4%–37.3%) for those who did not; it was also higher at 7 years (75.6%, 72.7%–78.5%, compared with 55.5%, 49.7%–61.3%).ConclusionInitiating the vaccine series at the on-reserve community health centre had a positive impact on coverage. The ability to measure accurate coverage through data-sharing agreements and vaccine record linkage will support First Nations communities in identifying individual and community immunity. The findings also support the transfer of health funding and service delivery to First Nations to improve childhood immunisation uptake.
Contribution of collagen XIII to lung function and development of pulmonary fibrosis
Authors: Norman Oula , Koivunen Jarkko , Kaarteenaho Riitta , Salo Antti M , Mäki Joni M , Myllyharju Johanna , Pihlajaniemi Taina , Heikkinen Anne 
Published: December 2023

BackgroundCollagen XIII is a transmembrane collagen associated with neuromuscular junction development, and in humans its deficiency results in congenital myasthenic syndrome type 19 (CMS19), which leads to breathing difficulties. CMS19 patients usually have restricted lung capacity and one patient developed chronic lung disease. In single-cell RNA sequencing studies, collagen XIII has been identified as a marker for pulmonary lipofibroblasts, which have been implicated in the resolution of pulmonary fibrosis.MethodsWe investigated the location and function of collagen XIII in the lung to understand the origin of pulmonary symptoms in human CMS19 patients. Additionally, we performed immunostainings on idiopathic pulmonary fibrosis (IPF) samples (N=5) and both normal and fibrotic mouse lung. To study whether the lack of collagen XIII predisposes to restrictive lung disease, we exposedCol13a1-modified mice to bleomycin-induced pulmonary fibrosis.ResultsApparently normal alveolar septum sections of IPF patients′ lungs stained faintly for collagen XIII, and its expression was pinpointed to the septal fibroblasts in the mouse lung. Lung capacity was increased in mice lacking collagen XIII by over 10%. In IPF samples, collagen XIII was expressed by basal epithelial cells, hyperplastic alveolar epithelial cells and stromal cells in fibrotic areas, but the development of pulmonary fibrosis was unaffected in collagen XIII-deficient mice.ConclusionsChanges in mouse lung function appear to represent a myasthenic manifestation of collagen XIII deficiency. We suggest that respiratory muscle myasthenia is the primary cause of the breathing problems suffered by CMS19 patients in addition to skeletal deformities. Induction of collagen XIII expression in the IPF patients′ lungs warrants further studies to reveal collagen XIII-dependent disease mechanisms.
Discovery of U2AF1 neoantigens in myeloid neoplasms
Authors: Biernacki Melinda Ann , Lok Jessica , Black Ralph Graeme , Foster Kimberly A , Cummings Carrie , Woodward Kyle B , Monahan Tim , Oehler Vivian G , Stirewalt Derek L , Wu David , Rongvaux Anthony , Deeg Hans Joachim , Bleakley Marie 
Published: December 2023

BackgroundMyelodysplastic syndromes (MDS) arise from somatic mutations acquired in hematopoietic stem and progenitor cells, causing cytopenias and predisposing to transformation into secondary acute myeloid leukemia (sAML). Recurrent mutations in spliceosome genes, includingU2AF1, are attractive therapeutic targets as they are prevalent in MDS and sAML, arise early in neoplastic cells, and are generally absent from normal cells, including normal hematopoietic cells. MDS and sAML are susceptible to T cell-mediated killing, and thus engineered T-cell immunotherapies hold promise for their treatment. We hypothesized that targeting spliceosome mutation-derived neoantigens with transgenic T-cell receptor (TCR) T cells would selectively eradicate malignant cells in MDS and sAML.MethodsWe identified candidate neoantigen epitopes from recurrent protein-coding mutations in the spliceosome genesSRSF2andU2AF1using a multistep in silico process. Candidate epitopes predicted to bind human leukocyte antigen (HLA) class I, be processed and presented from the parent protein, and not to be subject to tolerance then underwent in vitro immunogenicity screening. CD8+T cells recognizing immunogenic neoantigen epitopes were evaluated in in vitro assays to assess functional avidity, confirm the predicted HLA restriction, the potential for recognition of similar peptides, and the ability to kill neoplastic cells in an antigen-specific manner. Neoantigen-specific TCR were sequenced, cloned into lentiviral vectors, and transduced into third-party T cells after knock-out of endogenous TCR, then tested in vitro for specificity and ability to kill neoplastic myeloid cells presenting the neoantigen. The efficacy of neoantigen-specific T cells was evaluated in vivo in a murine cell line-derived xenograft model.ResultsWe identified two neoantigens created from a recurrent mutation inU2AF1, isolated CD8+T cells specific for the neoantigens, and demonstrated that transferring their TCR to third-party CD8+T cells is feasible and confers specificity for the U2AF1 neoantigens. Finally, we showed that these neoantigen-specific TCR-T cells do not recognize normal hematopoietic cells but efficiently kill malignant myeloid cells bearing the specific U2AF1 mutation, including primary cells, in vitro and in vivo.ConclusionsThese data serve as proof-of-concept for developing precision medicine approaches that use neoantigen-directed T-cell receptor-transduced T cells to treat MDS and sAML.
On the Independent Coloring of Graphs with Applications to the Independence Number of Cartesian Product Graphs
Authors: Pleanmani Nopparat , Panma Sayan , Nupo Nuttawoot 
Published: December 2023

Let

G

be a graph with

V
=
V

G

. A nonempty subset

S

of

V

is called an independent set of

G

if no two distinct vertices in

S

are adjacent. The union of a class {

S
:
S

is an independent set of

G

} and

∅

is denoted by

I

G

. For a graph

H

, a function

f
:
V
⟶
I

H

is called an

H
−

independent coloring of

G

(or simply called an

H
−

coloring) if

f

x

∩
f

y

=
∅

for any adjacent vertices

x
,
y
∈
V

and

f

V

is a class of disjoint sets. Let

α

H
,
G

denote the maximum cardinality of the set{

∑

x
∈
V

f

x

:
f

is an

H
−

coloring of

G

}. In this paper, we obtain basic properties of an

H
−

coloring of

G

and find

α

H
,
G

of some families of graphs

G

and

H

. Furthermore, we apply them to determine the independence number of the Cartesian product of a complete graph

K

n

and a graph

G

and prove that

α

K

n

□
G

=
α

K

n

,
G

.
In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease
Authors: Landolff Quentin , Quillot Marine , Picard Fabien , Henry Patrick , Sideris Georgios , Bizeau Olivier , Piot Christophe , Jouve Bernard , Rischner Jérôme , Mejri Mourad , Charmasson Claude , Lasserre Raphael , Pouliquen Hervé , Joseph Thierry , Monsegu Jacques , Karsenty Bernard , Martin Yuste Victoria , Richet Nicolas , Lapeyre Guy , Beverelli Fabrizio , Beygui Farzin , Koning René 
Published: December 2023

Objectives. The aim of this postmarket clinical study was to assess the safety and efficacy of the latest generation polymer-free sirolimus-eluting stents (PF-SES) in an all-comers population comparing outcomes in stable coronary artery disease (CAD) versus acute coronary syndrome (ACS) in France. Background. The efficacy and safety of the first-generation PF-SES have already been demonstrated by randomized controlled trials and “all-comers” observational studies. Methods. For this all-comers observational, prospective, multicenter study, 1456 patients were recruited in 22 French centers. The primary endpoint was target lesion revascularization (TLR) rate at 12 months and secondary endpoints included major adverse cardiac events (MACE) and bleeding. Results. 895 patients had stable CAD and 561 had ACS. At 12 months, 2% of patients had a TLR, with similar rates between stable CAD and ACS (1.9% vs 2.2%,

p

= 0.7). The overall MACE rate was 5.2% with an expected higher rate in patients with ACS as compared to those with stable CAD (7.3% vs 3.9%,

p

= 0.007). The overall bleeding event rate was 4.5%, with similar rates in stable CAD as compared to ACS patients (3.8% vs 5.6%,

p

= 0.3). Dual antiplatelet therapy (DAPT) interruptions prior to the recommended duration occurred in 41.7% of patients with no increase in MACE rates as compared to patients who did not prematurely interrupt DAPT (3.9% vs 6.1%,

p

= 0.073). Conclusions. The latest generation PF-SES is associated with low clinical event rates in these all-comers patients. There was a high rate of prematurely terminated DAPT, without any effect on MACE at 12 months. This trial is registered with NCT03809715.